Why is SCHOTT Pharma stock rallying today?
SCHOTT Pharma shares surged 3.0% to €22.25 after Barclays upgraded the stock to Overweight, setting a price target of €27. Analyst Jonathon Unwin highlighted that three years of declining profit expectations are expected to reverse due to renegotiated customer contracts, particularly in the glass syringe segment. The company also shows promise in ready-to-use primary packaging and specialty vials for unstable drug formulations.
Berenberg independently raised its price target to €27, aligning with Barclays' bullish outlook. After a strong Q3 2026 earnings report with 8.3% revenue growth and higher full-year guidance, SCHOTT Pharma's stock reached a new 52-week high. The market rally was fueled by company-specific catalysts rather than broader market support, as U.S. equities slipped.
Prior sector headwinds, including destocking and sluggish demand for polymer-based syringes, seem to have passed.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
